Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · IEX Real-Time Price · USD
4.500
+0.600 (15.38%)
At close: Jul 19, 2024, 4:00 PM
4.510
+0.010 (0.22%)
Pre-market: Jul 22, 2024, 7:31 AM EDT
Can-Fite BioPharma Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Can-Fite BioPharma stock have an average target of 14, with a low estimate of 10 and a high estimate of 18. The average target predicts an increase of 211.11% from the current stock price of 4.50.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CANF stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| EF Hutton | EF Hutton | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +122.22% | Jul 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +300.00% | May 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $34 → $18 | Strong Buy | Maintains | $34 → $18 | +300.00% | Oct 24, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $34 | Strong Buy | Reiterates | $34 | +655.56% | Jun 2, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $34 | Strong Buy | Reiterates | $34 | +655.56% | Mar 13, 2023 |
Financial Forecast
Revenue This Year
3.40M
from 743.00K
Increased by 356.93%
Revenue Next Year
3.40M
from 3.40M
EPS This Year
-5.54
from -3.00
EPS Next Year
-5.39
from -5.54
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 3.9M | 3.9M | 3.1M |
| Avg | 3.4M | 3.4M | 3.0M |
| Low | 2.9M | 2.9M | 2.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 424.5% | 14.8% | -8.9% |
| Avg | 356.9% | - | -11.5% |
| Low | 288.4% | -15.0% | -15.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -5.03 | -4.33 | -7.73 |
| Avg | -5.54 | -5.39 | -7.51 |
| Low | -5.95 | -6.31 | -7.22 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.